ClinicalTrials.gg
CompletedNCT02954692EASEUpdated Jan 14, 2019

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

A Phase 4 interventional study of INSULIN GLARGINE (U300) and metformin in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.

Enrollment
136th of 178
112 · median 334
Started
2016
with 12 others
Phase 4
75 of 186
1 open now
Registered
147th of 186
by date

Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 136th largest by enrollment of the 178 interventional ones that give a count, is one of 13 that started in 2016, is one of 75 in phase 4, and was the 147th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Diabetes Mellitus, Type 2 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To assess the mean change in HbA1c (glycated haemoglobin).

Secondary Objectives:

To evaluate the efficacy and safety of the titration of insulin glargine U300 in terms of:

  • Targeted HbA1c;
  • Targeted fasting self- monitoring blood glucose (SMBG);
  • Hypoglycemic events;
  • Adverse events;
  • Quality of life assessment by DTSQs (Diabetes Treatment Satisfaction Questionnaire status) and DTSQc (Diabetes Treatment Satisfaction Questionnaire change);
  • Blood glucose fluctuation by using continuous glucose monitoring system (CGMS) in subgroup patients.
Read the detailed description

The total study duration per patient will be 27 weeks (2 weeks of screening, 24 weeks on treatment, and 1 week follow-up period).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with type 2 diabetes mellitus (≥18 years of age).
  • Type 2 diabetes mellitus diagnosis ≥1 year.
  • Treated with ≥1 oral antidiabetics (±glucagon like peptid-1 (GLP-1) analogue) without insulin, for at least 6 months and level between 8-11% (insulin-naïve).
  • Stable antidiabetic treatment for at least 3 months.
  • Willingness to adherence to treatment and titration (including self-injection, self- monitoring blood glucose [SMBG]).
  • Signed obtained.

Exclusion criteria

Exclusion criteria:

  • Age \<18 years old.
  • Type 1 diabetes mellitus.
  • Having secondary type 2 diabetes mellitus.
  • Use of any insulin therapy including premix, basal plus/basal bolus regimen from the diagnosis.
  • History of hypoglycemia unawareness.
  • Known /intolerance to insulin glargine or any of its .
  • Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol.
  • Use of systemic for two weeks or more within 12 weeks prior to the time of screening.
  • Pregnant or lactating women.
  • Participation in another clinical trial.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Insulin glargine (U300)

    Insulin glargine (U300) will be administered daily through subcutaneous injection, and thereafter, dose will be titrated weekly (preferably 3-4 days) as needed. Background non-insulin anti-diabetic drugs approved for use in combination with insulin according to local labelling, will be permitted, with the exception of Thiazolidinediones (TZDs), which must be stopped at the time of basal insulin initiation.

    Drug: INSULIN GLARGINE (U300) · Drug: metformin · Drug: sulfonylurea · Drug: meglitinides · Drug: thiazolidinediones · Drug: alpha-glucosidase inhibitors · Drug: GLP1 Receptor Agonist · Drug: Dipeptidyl peptidase-IV (DPP-IV) inhibitors · Drug: Sodium-glucose transport-2 (SGLT-2) inhibitors

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in HbA1c

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of patients achieving targeted fasting self-monitored blood glucose (SMBG) without experiencing severe and/or confirmed hypoglycemia ≤70mg/dL and <54 mg/dL

    Time frame: At Weeks 12 and 24

  2. Percentage of patients reaching targeted fasting SMBG (80-130 mg/dL)

    Time frame: At Weeks 12 and 24

  3. Duration to reach target pre-breakfast SMBG

    Time frame: Baseline, Week 24

  4. Mean change from baseline in HbA1c

    Time frame: Baseline, Week 12

  5. Mean change from baseline in SMBG

    Time frame: Baseline, Weeks 12, and 24

  6. Mean change from baseline in fasting plasma glucose (FPG)

    Time frame: Baseline, Weeks 12, and 24

  7. Mean change from baseline in Diabetes Treatment Satisfaction Questionnaire (DTSO) scores

    Time frame: Baseline, Week 24

07

Study locations

1 site
  • Turkey, Turkey
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Nov 3, 2016
Start
Nov 30, 2016
Primary completionActual
Dec 22, 2017
CompletionActual
Dec 22, 2017
Last update
Jan 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02954692
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 3, 2016
Start date
Nov 30, 2016
Primary completion
Dec 22, 2017
Completion
Dec 22, 2017
Last update
Jan 14, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion